Le Lézard
Classified in: Health, Business
Subject: FINANCING AGREEMENTS

SOLVE FSHD invests US$10 Million in Vita Therapeutics


VANCOUVER, British Columbia, Oct. 13, 2022 (GLOBE NEWSWIRE) -- SOLVE FSHD, a venture-philanthropic organization catalyzing the pace of innovation to accelerate a cure for facioscapulohumeral muscular dystrophy (FSHD), announced today an investment of US$10M million in Vita Therapeutics; a cell engineering company harnessing the power of genetics to develop novel cellular therapies to treat muscular dystrophies and solid tumours.

Chip Wilson, founder of lululemon athletica and SOLVE FSHD said, "Living with FSHD for over 30 years, my upper body muscles are quite wasted. We are hopeful that the Vita cell therapy approach will stimulate muscle regeneration and will help people like me to build up muscle faster than it breaks down."

The investment is part of a $31M Series B financing round led by Cambrian Biopharma. In addition to Solve FSHD joining, other new investors included Riptide Ventures and Cedars Sinai, which participated alongside TEDCO and other existing investors. Proceeds from the financing will be used to advance Vita's lead pre-clinical program VTA-100 for limb-girdle muscular dystrophy (LGMD2A) to the clinic. It will also fund the development of Vita's newest program, VTA-120, for the treatment of patients with FSHD and to further expand Vita's discovery pipeline. Since inception, Vita has raised a total of $66 million.

"Currently there are no treatments available for FSHD, and there is an urgent need to develop disease-modifying treatments that not only regenerate muscle but also correct the genetic defect that otherwise leads to the muscle's inability to repair itself," said Eva Chin, Executive Director for SOLVE FSHD. "We are pleased to support Vita as they continue to expand their induced pluripotent stem cell (iPSC) technology towards FSHD while further progressing their treatment for LGMD."

About SOLVE FSHD
SOLVE FSHD is funding innovative biotech and biopharma research and development activities that accelerate novel treatments for Facioscapulohumeral muscular dystrophy (FSHD). It is fully funded and created by Canadian entrepreneur and philanthropist Chip Wilson. The founder of yoga-inspired athletic apparel company lululemon athletica inc. has been living with FSHD for the last three decades of his life. He has committed $100 million of his own money to create SOLVE FSHD and kick-start funding into projects that fit the organization's mission: accelerate research into new therapies and find a cure for the disorder by 2027. https://solvefshd.com/ 

For early-stage companies, contact Solve FSHD at info@solvefshd.com.

If you have FSHD and want to find out about clinical trials or be included in the FSHD registry, please see Solve FSHD's website - https://solvefshd.com/

About Vita Therapeutics
Vita Therapeutics is a biotechnology company developing state-of-the-art cellular therapeutics for the treatment of debilitating neuromuscular diseases and cancers. Vita Therapeutics uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are

defective in patients. The Company is progressing its lead program VTA-100 for the treatment of limb-girdle muscular dystrophy (LGMD2A) with the goal of filing an Investigational New Drug Application with the US Food and Drug Administration in the next 18 months. Long term, the Company is developing its pipeline of cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics is currently working with numerous partners, including PanCella, Wyss Institute, and Johns Hopkins University, to advance their clinical programs. Learn more about the company at www.Vitatx.com

Media inquiries, please contact:
Carla Bosacki, Account Director
PR Associates
cbosacki@prassociates.com
T: 416-522-9677 



These press releases may also interest you

8 fév 2023
Tivic Health® Systems, Inc. ("Tivic") , a commercial-phase health technology company that develops and commercializes bioelectronic medicine, today announced the pricing of an underwritten public offering of an aggregate of 20,000,000 shares of...

8 fév 2023
The global liver cancer drugs market size is estimated to increase by USD 5.29 billion from 2021 to 2026. The market's growth momentum will accelerate at a CAGR of 14.67%. The report provides a comprehensive analysis of growth opportunities at...

8 fév 2023
Rare Cannabinoid Company has announced a special offer for customers to try their extra strength THCV gummies for appetite suppression and energy and CBD gummies for stress resilience. The premium Hawaiian company is encouraging cannabis and hemp...

8 fév 2023
Bioceres Crop Solutions Corp. (Bioceres) , a fully integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, announced financial results for the fiscal second quarter ended December...

8 fév 2023
GC Biopharma (006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that the World Health Organization (WHO) has awarded prequalification to filling and finish plant on February 3 2023, located in Ochang, South...

8 fév 2023
The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. The report...



News published on 13 october 2022 at 11:00 and distributed by: